TMCnet News
PixarBio Builds Commercialization Team Adding Regulatory Affairs, cGMP Manufacturing, Sales/Bus Dev, and Medical AffairsPixarBio Corporation today announced expansion of the leadership team, to maintain momentum toward multiple FDA approvals of non-opiate and non-addictive pain treatments in 2017. Dr. Amer Khalil, PixarBio scientific advisory board member has accepted the role of Medical Director. Dr. Khalil, a Harvard trained Neurosurgeon is a long-time collaborator with PixarBio cofounder Frank Reynolds having worked for Mr. Reynolds at InVivo Therapeutics. Mr. Glenn Reiser joins PixarBio to serve as Director Business Development/Sales from Pacira Pharmaceuticals where he was Director, National Accounts responsible for post-op pain's leading treatment Exparel. Sarah Scott provides leadership on key aspects of cGMP manufacturing while Paul Dawidczyk will assume the Sr. Director of Regulatory Affairs role and lead FDA meetings in Q3 2015. "Alternatives to opiates such as morphine, Percocet, and Vicodin and other addictive pain treatments are a societal mandate that we believe we have solved. Building the best place to work in Boston and the USA is easy when your team changes science and medicine every day. Our additional tem members will support our human studies in 2016 and drive our wide portfolio of inventions to market. We've extended our RSB based platform by concurrently engineering multiple products, in addition to pain treatments to treat a range of neurological problems. New products for epilepsy, dentistry, spinal cord injury, chronic pain, and Parkinson's Disease are in our portfolio," said PixarBio CEO Frank Reynolds. "We are excited to expand our existing team of industry experts," continued Frank Reynolds. "Glenn Reiser's background and experience is a great fit to move PixarBio's portfolio toward monetization. Glenn will report to me and build upon established and targeted strategic partnerships in pain, dentistry, epilepsy, neurotrauma, spinal cord injury, cancer, and Parkinsons Disease. In addition, Sarah Scott strengthens our manufacturing capabilities accelerating and compressing industry learning curves and time to market. I'm especially pleased to complement my US FDA regulatory expertise with Paulie D's as we prepare our portfolio for a wide range of IND/NDAs submissions between 2016-2020." …Onward and Upward!! About PixarBio Corporation PixarBio Corporation is developing a targeted delivery platform to treat pain, epilepsy, Parkinson's disease, and spinal cord injury. Cofounded by Frank Reynolds, MIT's (News - Alert) Dr. Robert S. Langer, Katrin Holzhaus, and Jason Criscione, PixarBio is focused on researching and developing targeted delivery system for acute and chronic neurological conditions. For more information visit www.pixarbio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150828005036/en/ |
